Interestingly, progressive but fludarabine-sensitive patients did not show BIRC3 aberrations, suggesting that BIRC3 genetic lesions are specifically associated with a chemorefractory CLL phenotype [50]. The gene discussed is BIRC3; the disease is B-cell chronic lymphocytic leukemia.